1 reports of this reaction
3.7% of all STRYCHNOS IGNATII SEED reports
#7 most reported adverse reaction
BREAST CANCER is the #7 most commonly reported adverse reaction for STRYCHNOS IGNATII SEED, manufactured by Aurobindo Pharma Limited. There are 1 FDA adverse event reports linking STRYCHNOS IGNATII SEED to BREAST CANCER. This represents approximately 3.7% of all 27 adverse event reports for this drug.
Patients taking STRYCHNOS IGNATII SEED who experience breast cancer should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BREAST CANCER is moderately reported among STRYCHNOS IGNATII SEED users, representing a notable but not dominant share of adverse events.
In addition to breast cancer, the following adverse reactions have been reported for STRYCHNOS IGNATII SEED:
The following drugs have also been linked to breast cancer in FDA adverse event reports:
BREAST CANCER has been reported as an adverse event in 1 FDA reports for STRYCHNOS IGNATII SEED. This does not prove causation, but indicates an association observed in post-market surveillance data.
BREAST CANCER accounts for approximately 3.7% of all adverse event reports for STRYCHNOS IGNATII SEED, making it a notable side effect.
If you experience breast cancer while taking STRYCHNOS IGNATII SEED, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.